Table 3.

Relation of Response with Pharmacokinetic Parameters.

	Unit	Total	Favorable response (N = 64)	Unfavorable response (N = 37)	P-value
		(Mean ± SD)	Mean ± SD	Mean ± SD
IM level
Peak	ng/ml	2,423 ± 902	2,378 ± 893	2,433 ± 927	0.45
Trough	ng/ml	1,199 ± 506	1,281 ± 578	935 ± 559	0.006*
P/T ratio		2.4 ± 1.5	2.06 ± 0.8	2.8 ± 2.1	0.001*
N-des-methyl imatinib
Peak	ng/ml	311.1 ± 129.2	306 ± 131	320 ± 128	0.61
Trough	ng/ml	208.8 ± 98.2	217 ± 94	192 ± 104	0.22
P/T ratio		1.71 ± 1.33	1.51 ± 0.52	2.13 ± 2.09	0.095
Pyridine-N-oxide imatinib
Peak	ng/ml	37.1 ± 22.0	38.2 ± 24.3	35.5 ± 17.2	0.52
Trough	ng/ml	16.8 ± 12.6	18.8 ± 14.2	13.2 ± 8.1	0.01*
P/T ratio		2.78 ± 2.13	2.06 ± 0.79	3.12 ± 2.09	0.008*
Pharmacokinetic parameters
Ke		0.034 (0.0005–0.11)	0.029 ± 0.018	0.040 ± 0.021	<0.001*
CSS	ng/ml	1,769 ± 689	1,840 ± 679	1,684 ± 706	0.22
Vd	L	186 ±81.7	192 ± 89	166 ± 64	0.41
Cl	L/hr	158 ± 147	128 ± 137	175 ± 158	0.004*
Alph-1-acid gp	μg/ml	1.62 ± 0.52	1.62 ± 0.55	1.58 ± 0.44	0.68

^*P value is significant ≤ 0.05.

IM, Imatinib; K_e, elimination constant; C_SS, IM Steady State plasma Concentration; V_d, Volume of distribution; Cl, IM Clearance; P/T, Peak/Trough ratio.